Anti-bacterial and anti-toxic immunity induced by a killed whole-cell-cholera toxin B subunit cholera vaccine is essential for protection against lethal bacterial infection in mouse pulmonary cholera model

Mucosal Immunology

Volumn 6, Issue 4, 2013, Pages 826-837

  Kang, S S ^a   Yang, J S ^a   Kim, K W ^a,b   Yun, C H ^b   Holmgren, J ^c   Czerkinsky, C ^a   Han, S H ^a,d  

^a International Vaccine Institute   (South Korea)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d BK 21 Plus   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; KILLED WHOLE CELL CHOLERA TOXIN B SUBUNIT CHOLERA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; CHOLERA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNITY; LOBAR PNEUMONIA; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PULMONARY CHOLERA; VIBRIO CHOLERAE;

EID: 84879357473     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.121     Document Type: Article

References (50)

1. Lopez, A.L., Clemens, J.D., Deen, J. & Jodar, L. Cholera vaccines for the developing world. Hum. Vaccine 4, 165-169 (2008).
2. Butler, S.M. & Camilli, A. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat. Rev. Microbiol. 3, 611-620 (2005).
3. Provenzano, D., Kovac, P. & Wade, W.F. The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine. Microbiol. Immunol. 50, 899-927 (2006).
4. Sack, D.A., Sack, R.B., Nair, G.B. & Siddique, A.K. Cholera. Lancet 363, 223-233 (2004).
5. Ramamurthy, T. et al. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet 341, 703-704 (1993).
6. Taylor, R.K., Miller, V.L., Furlong, D.B. & Mekalanos, J.J. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc. Natl. Acad. Sci. USA 84, 2833-2837 (1987).
7. Fullner, K.J., Lencer, W.I. & Mekalanos, J.J. Vibrio cholerae-induced cellular responses of polarized T84 intestinal epithelial cells are dependent on production of cholera toxin and the RTX toxin. Infect. Immun. 69, 6310-6317 (2001).
8. Burnet, F.M. Ovomucin as a substrate for the mucinolytic enzymes of V cholerae filtrates. Aust. J. Exp. Biol. Med. Sci. 27, 245-252 (1949).
9. Ryan, E.T., Calderwood, S.B. & Qadri, F. Live attenuated oral cholera vaccines. Expert Rev. Vaccines 5, 483-494 (2006).
10. Kaper, J.B., Morris Jr J.G. & Levine, M.M. Cholera. Clin. Microbiol. Rev. 8, 48-86 (1995).
11. Cox, E., Verdonck, F., Vanrompay, D. & Goddeeris, B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res. 37, 511-539 (2006).
12. Sanchez, J. & Holmgren, J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell. Mol. Life Sci. 65, 1347-1360 (2008).
13. Hill, D.R., Ford, L. & Lalloo, D.G. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis. 6, 361-373 (2006).
14. Jelinek, T. & Kollaritsch, H. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera. Expert Rev. Vaccines 7, 561-567 (2008).
15. Anh, D.D. et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25, 1149-1155 (2007).
16. Sur, D. et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 374, 1694-1702 (2009).
17. Simanjuntak, C.H. et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24-to 59-month-old Indonesian children. J. Infect. Dis. 168, 1169-1176 (1993).
18. Richardson, S.H. Animal models in cholera research. In Vibrio Cholerae and Cholera: Molecular to Global Perspectives (Wachsmuth, P.A.B. & Olsvik, Ø., eds) 203-226 (ASM Press, Washington, D. C., 1994).
19. Klose, K.E. The suckling mouse model of cholera. Trends Microbiol. 8, 189-191 (2000).
20. Chen, I., Finn, T.M., Yanqing, L., Guoming, Q., Rappuoli, R. & Pizza, M. A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infect. Immun. 66, 1648-1653 (1998).
21. Butterton, J.R., Ryan, E.T., Shahin, R.A. & Calderwood, S.B. Development of a germfree mouse model of Vibrio cholerae infection. Infect. Immun. 64, 4373-4377 (1996).
22. Macpherson, A.J. & Uhr, T. Compartmentalization of the mucosal immune responses to commensal intestinal bacteria. Ann. NY Acad. Sci. 1029, 36-43 (2004).
23. Nygren, E., Li, B.L., Holmgren, J. & Attridge, S.R. Establishment of anadult mouse model for direct evaluation of the efficacy of vaccines against Vibrio cholerae. Infect. Immun. 77, 3475-3484 (2009).
24. Fullner, K.J. etal. The contributionofaccessory toxinsof Vibrio choleraeO1 El Tor to the proinflammatory response in a murine pulmonary cholera model. J. Exp. Med. 195, 1455-1462 (2002).
25. Makri, S., Purdy, A.E., Bartlett, D. & Fierer, J. Pathogenicity of environmental isolates of V. cholerae in mice. Microbes Infect. 9, 1351-1358 (2007).
26. Padilla, N.D., Ciurana, C., van Oers, J., Ogilvie, A.C. & Hack, C.E. Levels of natural IgM antibodies against phosphorylcholineinhealthy individuals and in patients undergoing isolated limb perfusion. J. Immunol. Methods 293, 1-11 (2004).
27. Meeks, M.D. et al. Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. Infect. Immun. 72, 4090-4101 (2004).
28. Svennerholm, A.M., Jertborn, M., Gothefors, L., Karim, A.M., Sack, D.A. & Holmgren, J. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J. Infect. Dis. 149, 884-893 (1984).
29. Black, R.E., Levine, M.M., Clements, M.L., Young, C.R., Svennerholm, A.M. & Holmgren, J. Protective efficacyinhumansofkilled whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun. 55, 1116-1120 (1987).
30. Holmgren, J. et al. An oral B subunit: whole cell vaccine against cholera. Vaccine 10, 911-914 (1992).
31. Schild, S., Nelson, E.J. & Camilli, A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect. Immun. 76, 4554-4563 (2008).
32. Nygren, E., Holmgren, J. & Attridge, S.R. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. Vaccine 26, 6784-6790 (2008).
33. Nandy, R.K., Albert, M.J. & Ghose, A.C. Serum antibacterial and antitoxin responses in clinical cholera caused by Vibrio cholerae O139 Bengal and evaluation of their importance in protection. Vaccine 14, 1137-1142 (1996).
34. Clemens, J.D. et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 2, 124-127 (1986).
35. Clemens, J.D. et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335, 270-273 (1990).
36. Czerkinsky, C., Sun, J.B. & Holmgren, J. Oral tolerance and anti-pathological vaccines. Curr. Top. Microbiol. Immunol. 236, 79-91 (1991).
37. Sun, J.B., Holmgren, J. & Czerkinsky, C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. USA 91, 10795-10799 (1994).
38. Poulter, L.W. Basic concepts inlung immunology. Res. Immunol.148, 8-13 (1997).
39. Elmore, S.A. Enhanced histopathology of mucosa-associated lymphoid tissue. Toxicol. Pathol. 34, 687-696 (2006).
40. Hofer, D. & Drenckhahn, D. Cytoskeletal markers allowing discrimination between brush cells and other epithelial cells of the gut including enteroendocrine cells. Histochem. Cell Biol. 105, 405-412 (1996).
41. Bals, R. Epithelial antimicrobial peptides in host defense against infection. Respir. Res. 1, 141-150 (2000).
42. Janardhan, K.S. et al. Toll like receptor-4 expression in lipopolysaccharide induced lung inflammation. Histol. Histopathol. 21, 687-696 (2006).
43. DiMango, E., Ratner, A.J., Bryan, R., Tabibi, S. & Prince, A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J. Clin. Invest. 101, 2598-2605 (1998).
44. Abreu, M.T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat. Rev. Immunol. 10, 131-144 (2010).
45. Holmgren, J., Lonnroth, I., Mansson, J. & Svennerholm, L. Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc. Natl. Acad. Sci. USA 72, 2520-2524 (1975).
46. Jonson, G., Sanchez, J. & Svennerholm, A.M. Expression and detection of different biotype-associated cell-bound haemagglutininsofVibrio cholerae O1. J. Gen. Microbiol. 135, 111-120 (1989).
47. Saha, A. et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29, 8285-8292 (2011).
48. Cuburu, N. et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25, 8598-8610 (2007).
49. Chang, S.Y. et al. Colonic patches direct the cross-talk between systemic compartments and large intestine independently of innate immunity. J. Immunol. 180, 1609-1618 (2008).
50. Yang., J.S. et al. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses. J. Micro-biol. Methods 71, 141-146 (2007).